Compile Data Set for Download or QSAR
Found 137 Enz. Inhib. hit(s) with Target = 'Atrial natriuretic peptide receptor 1'
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091751(CHEMBL411542 | Cyclic-(Cys-Phe-Gly-Gly-Arg-Ile-Asp...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](N)CSSC[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(O)=O)[C@@H](C)CC
Show InChI InChI=1S/C70H114N24O22S2/c1-8-35(5)55-66(113)83-28-50(98)84-37(7)57(104)88-42(19-20-48(72)96)62(109)92-46(31-95)61(108)82-29-52(100)86-43(23-34(3)4)59(106)81-30-53(101)87-47(68(115)116)33-118-117-32-39(71)58(105)90-44(24-38-15-11-10-12-16-38)60(107)80-26-49(97)79-27-51(99)85-40(17-13-21-77-69(73)74)63(110)94-56(36(6)9-2)67(114)91-45(25-54(102)103)65(112)89-41(64(111)93-55)18-14-22-78-70(75)76/h10-12,15-16,34-37,39-47,55-56,95H,8-9,13-14,17-33,71H2,1-7H3,(H2,72,96)(H,79,97)(H,80,107)(H,81,106)(H,82,108)(H,83,113)(H,84,98)(H,85,99)(H,86,100)(H,87,101)(H,88,104)(H,89,112)(H,90,105)(H,91,114)(H,92,109)(H,93,111)(H,94,110)(H,102,103)(H,115,116)(H4,73,74,77)(H4,75,76,78)/t35-,36-,37-,39+,40-,41-,42-,43-,44-,45-,46-,47+,55-,56-/m0/s1
Affinity DataKi:  0.100nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091758((S)-N-[(S)-4-Guanidino-1-((S)-2-methyl-butylcarbam...)
Show SMILES CC[C@H](C)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)Cc1ccc(NC(=O)c2ccc3ccccc3c2)cc1)[C@@H](C)CC
Show InChI InChI=1S/C43H59N9O8/c1-6-25(3)24-47-40(58)33(13-10-20-46-43(44)45)50-41(59)34(23-36(54)55)51-42(60)37(26(4)7-2)52-38(56)27(5)48-35(53)21-28-14-18-32(19-15-28)49-39(57)31-17-16-29-11-8-9-12-30(29)22-31/h8-9,11-12,14-19,22,25-27,33-34,37H,6-7,10,13,20-21,23-24H2,1-5H3,(H,47,58)(H,48,53)(H,49,57)(H,50,59)(H,51,60)(H,52,56)(H,54,55)(H4,44,45,46)/t25-,26-,27-,33-,34-,37-/m0/s1
Affinity DataKi:  0.300nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091752((S)-3-{(2S,3S)-2-[(S)-5-Guanidino-2-(2-{4-[(naphth...)
Show SMILES CC[C@H](C)CNC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)Cc1ccc(NC(=O)c2ccc3ccccc3c2)cc1)[C@@H](C)CC
Show InChI InChI=1S/C43H59N9O8/c1-6-25(3)24-47-38(56)27(5)48-41(59)34(23-36(54)55)51-42(60)37(26(4)7-2)52-40(58)33(13-10-20-46-43(44)45)50-35(53)21-28-14-18-32(19-15-28)49-39(57)31-17-16-29-11-8-9-12-30(29)22-31/h8-9,11-12,14-19,22,25-27,33-34,37H,6-7,10,13,20-21,23-24H2,1-5H3,(H,47,56)(H,48,59)(H,49,57)(H,50,53)(H,51,60)(H,52,58)(H,54,55)(H4,44,45,46)/t25-,26-,27-,33-,34-,37-/m0/s1
Affinity DataKi:  0.400nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091757(CHEMBL264744 | Cyclic-(Cys-Phe-Gly-Gly-Ala-Ile-Asp...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](N)CSSC[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(O)=O)[C@@H](C)CC
Show InChI InChI=1S/C67H107N21O22S2/c1-9-33(5)53-64(107)77-26-49(93)78-35(7)55(98)82-40(18-19-46(69)90)61(104)86-44(29-89)60(103)76-27-50(94)80-41(21-32(3)4)58(101)75-28-51(95)81-45(66(109)110)31-112-111-30-38(68)57(100)84-42(22-37-15-12-11-13-16-37)59(102)74-24-47(91)73-25-48(92)79-36(8)56(99)87-54(34(6)10-2)65(108)85-43(23-52(96)97)63(106)83-39(62(105)88-53)17-14-20-72-67(70)71/h11-13,15-16,32-36,38-45,53-54,89H,9-10,14,17-31,68H2,1-8H3,(H2,69,90)(H,73,91)(H,74,102)(H,75,101)(H,76,103)(H,77,107)(H,78,93)(H,79,92)(H,80,94)(H,81,95)(H,82,98)(H,83,106)(H,84,100)(H,85,108)(H,86,104)(H,87,99)(H,88,105)(H,96,97)(H,109,110)(H4,70,71,72)/t33-,34-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45+,53-,54-/m0/s1
Affinity DataKi:  0.490nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091753(CHEMBL405854 | H-Ser-Leu-Arg-Arg-Ser-Ser-cyclic(Cy...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](CSSC[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO
Show InChI InChI=1S/C127H203N45O39S3/c1-9-64(6)99-121(209)150-52-94(182)151-65(7)100(188)155-76(34-35-91(129)179)109(197)167-85(56-174)104(192)149-53-96(184)153-78(43-62(2)3)102(190)148-54-97(185)154-89(119(207)164-82(48-92(130)180)114(202)169-86(57-175)116(204)163-81(46-67-23-14-11-15-24-67)113(201)158-73(27-18-39-143-125(135)136)107(195)166-84(122(210)211)47-68-30-32-69(178)33-31-68)60-213-214-61-90(171-118(206)88(59-177)170-117(205)87(58-176)168-108(196)74(28-19-40-144-126(137)138)156-106(194)72(26-17-38-142-124(133)134)157-112(200)79(44-63(4)5)161-101(189)70(128)55-173)120(208)162-80(45-66-21-12-10-13-22-66)103(191)147-50-93(181)146-51-95(183)152-71(25-16-37-141-123(131)132)105(193)160-77(36-42-212-8)110(198)165-83(49-98(186)187)115(203)159-75(111(199)172-99)29-20-41-145-127(139)140/h10-15,21-24,30-33,62-65,70-90,99,173-178H,9,16-20,25-29,34-61,128H2,1-8H3,(H2,129,179)(H2,130,180)(H,146,181)(H,147,191)(H,148,190)(H,149,192)(H,150,209)(H,151,182)(H,152,183)(H,153,184)(H,154,185)(H,155,188)(H,156,194)(H,157,200)(H,158,201)(H,159,203)(H,160,193)(H,161,189)(H,162,208)(H,163,204)(H,164,207)(H,165,198)(H,166,195)(H,167,197)(H,168,196)(H,169,202)(H,170,205)(H,171,206)(H,172,199)(H,186,187)(H,210,211)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)(H4,139,140,145)/t64-,65-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84+,85-,86-,87-,88-,89+,90+,99-/m0/s1
Affinity DataKi:  0.650nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091761((S)-N-[(S)-4-Guanidino-1-((S)-2-methyl-butylcarbam...)
Show SMILES CC[C@H](C)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)Cc1ccc(NC(=O)c2ccc3ccccc3c2)cc1)[C@@H](C)CC
Show InChI InChI=1S/C46H66N12O8/c1-5-27(3)26-53-41(63)34(13-9-21-51-45(47)48)56-43(65)36(25-38(60)61)57-44(66)39(28(4)6-2)58-42(64)35(14-10-22-52-46(49)50)55-37(59)23-29-15-19-33(20-16-29)54-40(62)32-18-17-30-11-7-8-12-31(30)24-32/h7-8,11-12,15-20,24,27-28,34-36,39H,5-6,9-10,13-14,21-23,25-26H2,1-4H3,(H,53,63)(H,54,62)(H,55,59)(H,56,65)(H,57,66)(H,58,64)(H,60,61)(H4,47,48,51)(H4,49,50,52)/t27-,28-,34-,35-,36-,39-/m0/s1
Affinity DataKi: >10nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091754(Arg-Ser-Ser-cyclic-(Cys-Phe-Gly-Gly-Arg-Ile-Asp-Ar...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@H](C)NC(=O)CNC1=O)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC
Show InChI InChI=1S/C64H106N24O20S2/c1-6-31(3)48-59(105)77-26-45(92)78-33(5)50(96)86-43(61(107)108)30-110-109-29-42(85-57(103)41(28-90)84-56(102)40(27-89)83-51(97)35(65)16-11-19-72-62(66)67)58(104)81-38(22-34-14-9-8-10-15-34)52(98)76-24-44(91)75-25-46(93)79-36(17-12-20-73-63(68)69)53(99)88-49(32(4)7-2)60(106)82-39(23-47(94)95)55(101)80-37(54(100)87-48)18-13-21-74-64(70)71/h8-10,14-15,31-33,35-43,48-49,89-90H,6-7,11-13,16-30,65H2,1-5H3,(H,75,91)(H,76,98)(H,77,105)(H,78,92)(H,79,93)(H,80,101)(H,81,104)(H,82,106)(H,83,97)(H,84,102)(H,85,103)(H,86,96)(H,87,100)(H,88,99)(H,94,95)(H,107,108)(H4,66,67,72)(H4,68,69,73)(H4,70,71,74)/t31-,32-,33-,35-,36-,37-,38-,39-,40-,41-,42+,43+,48-,49-/m0/s1
Affinity DataKi: >10nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091759(CHEMBL59028 | Naphthalene-2-carboxylic acid (4-{[(...)
Show SMILES CC[C@H](C)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)Cc1ccc(NC(=O)c2ccc3ccccc3c2)cc1)[C@@H](C)CC
Show InChI InChI=1S/C45H66N12O6/c1-6-27(3)26-52-41(61)35(14-10-22-50-44(46)47)56-39(59)29(5)53-43(63)38(28(4)7-2)57-42(62)36(15-11-23-51-45(48)49)55-37(58)24-30-16-20-34(21-17-30)54-40(60)33-19-18-31-12-8-9-13-32(31)25-33/h8-9,12-13,16-21,25,27-29,35-36,38H,6-7,10-11,14-15,22-24,26H2,1-5H3,(H,52,61)(H,53,63)(H,54,60)(H,55,58)(H,56,59)(H,57,62)(H4,46,47,50)(H4,48,49,51)/t27-,28-,29-,35-,36-,38-/m0/s1
Affinity DataKi:  62nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091747((S)-N-[(S)-1-((S)-2-Methyl-butylcarbamoyl)-ethyl]-...)
Show SMILES CC[C@H](C)CNC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)Cc1ccc(NC(=O)c2ccc3ccccc3c2)cc1)[C@@H](C)CC
Show InChI InChI=1S/C40H52N6O8/c1-7-23(3)22-41-36(50)25(5)43-39(53)32(21-34(48)49)45-40(54)35(24(4)8-2)46-37(51)26(6)42-33(47)19-27-13-17-31(18-14-27)44-38(52)30-16-15-28-11-9-10-12-29(28)20-30/h9-18,20,23-26,32,35H,7-8,19,21-22H2,1-6H3,(H,41,50)(H,42,47)(H,43,53)(H,44,52)(H,45,54)(H,46,51)(H,48,49)/t23-,24-,25-,26-,32-,35-/m0/s1
Affinity DataKi:  65nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091750(CHEMBL415133 | Cyclic-(Cys-Phe-Gly-Gly-Arg-Ile-Ala...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](N)CSSC[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(O)=O)[C@@H](C)CC
Show InChI InChI=1S/C69H114N24O20S2/c1-9-35(5)54-65(110)82-28-50(97)83-37(7)56(101)89-43(20-21-48(71)95)62(107)91-46(31-94)61(106)81-29-52(99)86-44(24-34(3)4)59(104)80-30-53(100)87-47(67(112)113)33-115-114-32-40(70)58(103)90-45(25-39-16-12-11-13-17-39)60(105)79-26-49(96)78-27-51(98)85-41(18-14-22-76-68(72)73)63(108)93-55(36(6)10-2)66(111)84-38(8)57(102)88-42(64(109)92-54)19-15-23-77-69(74)75/h11-13,16-17,34-38,40-47,54-55,94H,9-10,14-15,18-33,70H2,1-8H3,(H2,71,95)(H,78,96)(H,79,105)(H,80,104)(H,81,106)(H,82,110)(H,83,97)(H,84,111)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,101)(H,90,103)(H,91,107)(H,92,109)(H,93,108)(H,112,113)(H4,72,73,76)(H4,74,75,77)/t35-,36-,37-,38-,40+,41-,42-,43-,44-,45-,46-,47+,54-,55-/m0/s1
Affinity DataKi:  87nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091749(CHEMBL412793 | Cyclic-(Cys-Phe-Gly-Gly-Arg-Ala-Asp...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](N)CSSC[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(O)=O
Show InChI InChI=1S/C67H108N24O22S2/c1-7-33(4)53-64(111)80-26-48(95)81-34(5)54(101)86-40(17-18-46(69)93)61(108)90-44(29-92)59(106)79-27-50(97)84-41(21-32(2)3)57(104)78-28-51(98)85-45(65(112)113)31-115-114-30-37(68)56(103)89-42(22-36-13-9-8-10-14-36)58(105)77-24-47(94)76-25-49(96)83-38(15-11-19-74-66(70)71)60(107)82-35(6)55(102)88-43(23-52(99)100)63(110)87-39(62(109)91-53)16-12-20-75-67(72)73/h8-10,13-14,32-35,37-45,53,92H,7,11-12,15-31,68H2,1-6H3,(H2,69,93)(H,76,94)(H,77,105)(H,78,104)(H,79,106)(H,80,111)(H,81,95)(H,82,107)(H,83,96)(H,84,97)(H,85,98)(H,86,101)(H,87,110)(H,88,102)(H,89,103)(H,90,108)(H,91,109)(H,99,100)(H,112,113)(H4,70,71,74)(H4,72,73,75)/t33-,34-,35-,37+,38-,39-,40-,41-,42-,43-,44-,45+,53-/m0/s1
Affinity DataKi:  360nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091755((S)-N-[(S)-4-Guanidino-1-((S)-2-methyl-pentylcarba...)
Show SMILES CCC[C@H](C)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)Cc1ccccc1)[C@@H](C)CC
Show InChI InChI=1S/C36H61N11O7/c1-5-12-22(3)21-43-31(51)25(15-10-17-41-35(37)38)45-33(53)27(20-29(49)50)46-34(54)30(23(4)6-2)47-32(52)26(16-11-18-42-36(39)40)44-28(48)19-24-13-8-7-9-14-24/h7-9,13-14,22-23,25-27,30H,5-6,10-12,15-21H2,1-4H3,(H,43,51)(H,44,48)(H,45,53)(H,46,54)(H,47,52)(H,49,50)(H4,37,38,41)(H4,39,40,42)/t22-,23-,25-,26-,27-,30-/m0/s1
Affinity DataKi:  539nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091748((S)-N-[(S)-4-Guanidino-1-((S)-2-methyl-butylcarbam...)
Show SMILES CC[C@H](C)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)Cc1ccc(NC(=O)c2ccc3ccccc3c2)cc1
Show InChI InChI=1S/C43H60N12O8/c1-4-25(2)24-50-39(61)32(11-7-19-48-42(44)45)54-41(63)34(23-36(57)58)55-37(59)26(3)51-40(62)33(12-8-20-49-43(46)47)53-35(56)21-27-13-17-31(18-14-27)52-38(60)30-16-15-28-9-5-6-10-29(28)22-30/h5-6,9-10,13-18,22,25-26,32-34H,4,7-8,11-12,19-21,23-24H2,1-3H3,(H,50,61)(H,51,62)(H,52,60)(H,53,56)(H,54,63)(H,55,59)(H,57,58)(H4,44,45,48)(H4,46,47,49)/t25-,26-,32-,33-,34-/m0/s1
Affinity DataKi:  680nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091760((S)-N-((S)-1-Carbamoyl-4-guanidino-butyl)-3-{2-[(S...)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)Cc1ccc(NC(=O)c2ccc3ccccc3c2)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
Show InChI InChI=1S/C41H56N12O8/c1-3-23(2)34(39(61)52-31(22-33(55)56)38(60)51-29(35(42)57)10-6-18-47-40(43)44)53-37(59)30(11-7-19-48-41(45)46)50-32(54)20-24-12-16-28(17-13-24)49-36(58)27-15-14-25-8-4-5-9-26(25)21-27/h4-5,8-9,12-17,21,23,29-31,34H,3,6-7,10-11,18-20,22H2,1-2H3,(H2,42,57)(H,49,58)(H,50,54)(H,51,60)(H,52,61)(H,53,59)(H,55,56)(H4,43,44,47)(H4,45,46,48)/t23-,29-,30-,31-,34-/m0/s1
Affinity DataKi:  2.60E+3nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50091756((S)-3-[(2S,3S)-2-((S)-2-Acetylamino-5-guanidino-pe...)
Show SMILES CCC[C@H](C)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)CC
Show InChI InChI=1S/C30H57N11O7/c1-6-10-17(3)16-37-25(45)20(11-8-13-35-29(31)32)39-27(47)22(15-23(43)44)40-28(48)24(18(4)7-2)41-26(46)21(38-19(5)42)12-9-14-36-30(33)34/h17-18,20-22,24H,6-16H2,1-5H3,(H,37,45)(H,38,42)(H,39,47)(H,40,48)(H,41,46)(H,43,44)(H4,31,32,35)(H4,33,34,36)/t17-,18-,20-,21-,22-,24-/m0/s1
Affinity DataKi:  2.90E+3nMAssay Description:Displacement of [125I]- ANP from the Atrial natriuretic peptide receptor A.More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254063(CHEMBL4102000)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NCC(=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO
Show InChI InChI=1S/C127H203N45O39S3/c1-9-64(6)99-121(209)150-53-94(182)151-65(7)100(188)154-76(34-35-91(129)179)108(196)166-85(56-174)103(191)149-54-96(184)153-78(43-62(2)3)115(203)171-97(185)51-146-89(119(207)163-82(48-92(130)180)113(201)168-86(57-175)116(204)162-81(46-67-23-14-11-15-24-67)112(200)157-73(27-18-39-143-125(135)136)106(194)165-84(122(210)211)47-68-30-32-69(178)33-31-68)60-213-214-61-90(170-118(206)88(59-177)169-117(205)87(58-176)167-107(195)74(28-19-40-144-126(137)138)155-105(193)72(26-17-38-142-124(133)134)156-111(199)79(44-63(4)5)160-101(189)70(128)55-173)120(208)161-80(45-66-21-12-10-13-22-66)102(190)148-50-93(181)147-52-95(183)152-71(25-16-37-141-123(131)132)104(192)159-77(36-42-212-8)109(197)164-83(49-98(186)187)114(202)158-75(110(198)172-99)29-20-41-145-127(139)140/h10-15,21-24,30-33,62-65,70-90,99,146,173-178H,9,16-20,25-29,34-61,128H2,1-8H3,(H2,129,179)(H2,130,180)(H,147,181)(H,148,190)(H,149,191)(H,150,209)(H,151,182)(H,152,183)(H,153,184)(H,154,188)(H,155,193)(H,156,199)(H,157,200)(H,158,202)(H,159,192)(H,160,189)(H,161,208)(H,162,204)(H,163,207)(H,164,197)(H,165,194)(H,166,196)(H,167,195)(H,168,201)(H,169,205)(H,170,206)(H,172,198)(H,186,187)(H,210,211)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)(H4,139,140,145)(H,171,185,203)/t64-,65-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,99-/m0/s1
Affinity DataIC50: 0.0940nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50333671(CHEMBL1643388)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(C)C
Show InChI InChI=1S/C143H244N50O42S4/c1-13-76(10)112-137(232)189-99(68-199)131(226)188-98(67-198)130(225)187-97(66-197)129(224)186-96(65-196)117(212)166-59-105(202)169-90(52-72(2)3)114(209)163-61-107(204)171-100(132(227)177-83(32-19-22-44-146)124(219)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)175-84(34-24-46-159-141(151)152)121(216)174-85(35-25-47-160-142(153)154)122(217)185-94(139(234)235)55-78-57-157-71-167-78)69-238-239-70-101(172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)179-120(215)82(31-18-21-43-145)180-134(229)102-37-27-49-193(102)138(233)79(147)63-194)133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(33-23-45-158-140(149)150)118(213)173-81(30-17-20-42-144)119(214)178-88(40-50-236-11)123(218)183-93(56-109(206)207)128(223)176-86(125(220)192-112)36-26-48-161-143(155)156/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,213)(H,174,216)(H,175,222)(H,176,223)(H,177,227)(H,178,214)(H,179,215)(H,180,229)(H,181,230)(H,182,228)(H,183,218)(H,184,231)(H,185,217)(H,186,224)(H,187,225)(H,188,226)(H,189,232)(H,190,219)(H,191,221)(H,192,220)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t76-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,110-,111-,112-/m0/s1
Affinity DataIC50: 6nMAssay Description:Displacement of [125I]ANP from NPR-A expressed in HeLa cells after 3 hrs by gamma countingMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50333672(CHEMBL1643389)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)c(c2)\N=N\c2ccc(C[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O)cc2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(C)C
Show InChI InChI=1S/C155H252N52O43S2/c1-13-83(10)124-149(247)201-112(77-213)145(243)200-111(76-212)144(242)199-110(75-211)143(241)198-109(74-210)129(227)178-69-117(217)181-101(58-79(2)3)126(224)175-68-118(218)182-104(140(238)187-93(32-19-22-50-158)136(234)202-123(82(8)9)148(246)196-102(59-80(4)5)139(237)188-94(34-24-52-171-153(163)164)133(231)186-95(35-25-53-172-154(165)166)134(232)197-107(151(249)250)64-88-66-169-78-179-88)61-85-38-41-87(42-39-85)205-206-100-62-86(40-44-114(100)214)63-105(183-119(219)70-177-128(226)108(73-209)184-120(220)71-174-125(223)97(43-45-115(160)215)193-147(245)122(81(6)7)203-138(236)99(47-57-252-12)191-132(230)92(31-18-21-49-157)192-146(244)113-37-27-55-207(113)150(248)89(159)72-208)141(239)194-103(60-84-28-15-14-16-29-84)127(225)176-67-116(216)180-90(33-23-51-170-152(161)162)130(228)185-91(30-17-20-48-156)131(229)190-98(46-56-251-11)135(233)195-106(65-121(221)222)142(240)189-96(137(235)204-124)36-26-54-173-155(167)168/h14-16,28-29,38-42,44,62,66,78-83,89-99,101-113,122-124,208-214H,13,17-27,30-37,43,45-61,63-65,67-77,156-159H2,1-12H3,(H2,160,215)(H,169,179)(H,174,223)(H,175,224)(H,176,225)(H,177,226)(H,178,227)(H,180,216)(H,181,217)(H,182,218)(H,183,219)(H,184,220)(H,185,228)(H,186,231)(H,187,238)(H,188,237)(H,189,240)(H,190,229)(H,191,230)(H,192,244)(H,193,245)(H,194,239)(H,195,233)(H,196,246)(H,197,232)(H,198,241)(H,199,242)(H,200,243)(H,201,247)(H,202,234)(H,203,236)(H,204,235)(H,221,222)(H,249,250)(H4,161,162,170)(H4,163,164,171)(H4,165,166,172)(H4,167,168,173)/t83-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-/m0/s1
Affinity DataIC50: 60nMAssay Description:Displacement of [125I]ANP from NPR-A expressed in HeLa cells after 3 hrs by gamma countingMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1/2/3(Homo sapiens (Human))
G. D. Searle & Co.

Curated by ChEMBL
LigandPNGBDBM50228173(CHEMBL2371607)
Show SMILES CC(C)C[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O
Show InChI InChI=1S/C49H84N20O15S/c1-25(2)17-31(65-38(75)27(50)21-70)42(79)64-28(11-6-14-57-47(51)52)40(77)63-29(12-7-15-58-48(53)54)41(78)67-33(22-71)43(80)68-34(23-72)44(81)69-35(24-85)45(82)66-32(18-26-9-4-3-5-10-26)39(76)61-19-36(73)60-20-37(74)62-30(46(83)84)13-8-16-59-49(55)56/h3-5,9-10,25,27-35,70-72,85H,6-8,11-24,50H2,1-2H3,(H,60,73)(H,61,76)(H,62,74)(H,63,77)(H,64,79)(H,65,75)(H,66,82)(H,67,78)(H,68,80)(H,69,81)(H,83,84)(H4,51,52,57)(H4,53,54,58)(H4,55,56,59)/t27-,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
Affinity DataIC50: 100nMAssay Description:Inhibitory activity against guanylate cyclase coupled receptor binding site in rabbit lung by using [125I]-ANP-(103-126)More data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254098(CHEMBL4098363)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](N)CS)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C46H83N17O12S/c1-5-24(3)36(43(74)56-20-32(48)64)62-41(72)29(15-11-17-54-46(51)52)59-42(73)31(19-35(67)68)61-44(75)37(25(4)6-2)63-40(71)28(14-10-16-53-45(49)50)58-34(66)22-55-33(65)21-57-39(70)30(60-38(69)27(47)23-76)18-26-12-8-7-9-13-26/h24-31,36-37,76H,5-23,47H2,1-4H3,(H2,48,64)(H,55,65)(H,56,74)(H,57,70)(H,58,66)(H,59,73)(H,60,69)(H,61,75)(H,62,72)(H,63,71)(H,67,68)(H4,49,50,53)(H4,51,52,54)/t24-,25-,27-,28-,29-,30-,31-,36-,37-/m0/s1
Affinity DataIC50: 120nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50333673(CHEMBL1643390)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H]1Cc2ccc(cc2)\N=N\c2nc[nH]c2C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC1=O)C(C)C)C(O)=O
Show InChI InChI=1S/C150H250N52O43S2/c1-14-79(10)117(143(241)195-106(73-208)139(237)194-105(72-207)138(236)193-104(71-206)137(235)192-103(70-205)124(222)171-65-110(212)176-96(57-75(2)3)121(219)169-64-111(213)177-99-60-82-39-41-83(42-40-82)200-201-119-95(173-74-174-119)61-101(146(244)245)191-129(227)90(36-26-52-166-149(160)161)180-128(226)89(35-25-51-165-148(158)159)182-134(232)97(58-76(4)5)189-142(240)116(78(8)9)197-131(229)88(181-135(99)233)33-20-23-49-153)199-132(230)91(37-27-53-167-150(162)163)183-136(234)100(62-114(216)217)188-130(228)93(45-55-246-12)184-126(224)86(31-18-21-47-151)179-125(223)85(34-24-50-164-147(156)157)175-109(211)63-170-122(220)98(59-81-29-16-15-17-30-81)190-144(242)118(80(11)209)196-113(215)67-172-123(221)102(69-204)178-112(214)66-168-120(218)92(43-44-108(155)210)187-141(239)115(77(6)7)198-133(231)94(46-56-247-13)185-127(225)87(32-19-22-48-152)186-140(238)107-38-28-54-202(107)145(243)84(154)68-203/h15-17,29-30,39-42,74-80,84-94,96-107,115-118,203-209H,14,18-28,31-38,43-73,151-154H2,1-13H3,(H2,155,210)(H,168,218)(H,169,219)(H,170,220)(H,171,222)(H,172,221)(H,173,174)(H,175,211)(H,176,212)(H,177,213)(H,178,214)(H,179,223)(H,180,226)(H,181,233)(H,182,232)(H,183,234)(H,184,224)(H,185,225)(H,186,238)(H,187,239)(H,188,228)(H,189,240)(H,190,242)(H,191,227)(H,192,235)(H,193,236)(H,194,237)(H,195,241)(H,196,215)(H,197,229)(H,198,231)(H,199,230)(H,216,217)(H,244,245)(H4,156,157,164)(H4,158,159,165)(H4,160,161,166)(H4,162,163,167)/t79-,80+,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,115-,116-,117-,118-/m0/s1
Affinity DataIC50: 240nMAssay Description:Displacement of [125I]ANP from NPR-A expressed in HeLa cells after 3 hrs by gamma countingMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254108(CHEMBL4062470)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(N)=O
Show InChI InChI=1S/C60H95N15O15/c1-7-33(3)48(50(61)81)72-52(83)39(22-15-25-64-60(62)63)68-55(86)42(30-47(79)80)70-58(89)49(34(4)8-2)73-57(88)44-23-16-26-74(44)46(78)31-65-51(82)35(5)66-53(84)41(29-38-20-13-10-14-21-38)69-56(87)45-24-17-27-75(45)59(90)43(32-76)71-54(85)40(67-36(6)77)28-37-18-11-9-12-19-37/h9,11-12,18-19,33-35,38-45,48-49,76H,7-8,10,13-17,20-32H2,1-6H3,(H2,61,81)(H,65,82)(H,66,84)(H,67,77)(H,68,86)(H,69,87)(H,70,89)(H,71,85)(H,72,83)(H,73,88)(H,79,80)(H4,62,63,64)/t33-,34-,35+,39-,40+,41-,42-,43-,44-,45+,48-,49-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254081(CHEMBL4103929)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)CNC1=O)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC
Show InChI InChI=1S/C64H106N24O20S2/c1-6-31(3)48-59(105)77-26-45(92)78-33(5)50(96)86-43(61(107)108)30-110-109-29-42(85-57(103)41(28-90)84-56(102)40(27-89)83-51(97)35(65)16-11-19-72-62(66)67)58(104)81-38(22-34-14-9-8-10-15-34)52(98)76-24-44(91)75-25-46(93)79-36(17-12-20-73-63(68)69)53(99)88-49(32(4)7-2)60(106)82-39(23-47(94)95)55(101)80-37(54(100)87-48)18-13-21-74-64(70)71/h8-10,14-15,31-33,35-43,48-49,89-90H,6-7,11-13,16-30,65H2,1-5H3,(H,75,91)(H,76,98)(H,77,105)(H,78,92)(H,79,93)(H,80,101)(H,81,104)(H,82,106)(H,83,97)(H,84,102)(H,85,103)(H,86,96)(H,87,100)(H,88,99)(H,94,95)(H,107,108)(H4,66,67,72)(H4,68,69,73)(H4,70,71,74)/t31-,32-,33-,35-,36-,37-,38-,39-,40-,41-,42-,43-,48-,49-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254095(CHEMBL4084171)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C62H98N16O16/c1-7-34(3)50(59(92)67-31-47(63)81)75-53(86)40(22-15-25-66-62(64)65)71-56(89)43(30-49(83)84)73-60(93)51(35(4)8-2)76-58(91)45-23-16-26-77(45)48(82)32-68-52(85)36(5)69-54(87)42(29-39-20-13-10-14-21-39)72-57(90)46-24-17-27-78(46)61(94)44(33-79)74-55(88)41(70-37(6)80)28-38-18-11-9-12-19-38/h9,11-12,18-19,34-36,39-46,50-51,79H,7-8,10,13-17,20-33H2,1-6H3,(H2,63,81)(H,67,92)(H,68,85)(H,69,87)(H,70,80)(H,71,89)(H,72,90)(H,73,93)(H,74,88)(H,75,86)(H,76,91)(H,83,84)(H4,64,65,66)/t34-,35-,36+,40-,41+,42-,43-,44-,45-,46+,50-,51-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254092(CHEMBL4062458)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C59H97N19O16/c1-6-32(3)48(56(93)68-27-43(60)81)77-53(90)38(21-15-23-66-59(63)64)74-55(92)41(26-47(85)86)75-57(94)49(33(4)7-2)78-52(89)37(20-14-22-65-58(61)62)72-45(83)29-67-44(82)28-69-50(87)39(24-35-16-10-8-11-17-35)73-46(84)30-70-51(88)42(31-79)76-54(91)40(71-34(5)80)25-36-18-12-9-13-19-36/h9,12-13,18-19,32-33,35,37-42,48-49,79H,6-8,10-11,14-17,20-31H2,1-5H3,(H2,60,81)(H,67,82)(H,68,93)(H,69,87)(H,70,88)(H,71,80)(H,72,83)(H,73,84)(H,74,92)(H,75,94)(H,76,91)(H,77,90)(H,78,89)(H,85,86)(H4,61,62,65)(H4,63,64,66)/t32-,33-,37-,38-,39-,40+,41-,42-,48-,49-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254089(CHEMBL4081715)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C66H112N24O18/c1-5-35(3)52(62(107)79-29-47(68)93)89-58(103)41(22-15-25-77-66(73)74)84-60(105)44(28-51(97)98)86-63(108)53(36(4)6-2)90-57(102)40(21-14-24-76-65(71)72)82-49(95)31-78-48(94)30-80-55(100)42(26-37-16-9-7-10-17-37)83-50(96)32-81-56(101)45(33-91)88-59(104)43(27-38-18-11-8-12-19-38)85-61(106)46(34-92)87-54(99)39(67)20-13-23-75-64(69)70/h8,11-12,18-19,35-37,39-46,52-53,91-92H,5-7,9-10,13-17,20-34,67H2,1-4H3,(H2,68,93)(H,78,94)(H,79,107)(H,80,100)(H,81,101)(H,82,95)(H,83,96)(H,84,105)(H,85,106)(H,86,108)(H,87,99)(H,88,104)(H,89,103)(H,90,102)(H,97,98)(H4,69,70,75)(H4,71,72,76)(H4,73,74,77)/t35-,36-,39-,40-,41-,42-,43-,44-,45-,46-,52-,53-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254086(CHEMBL4076700)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CN)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C45H81N17O12/c1-5-24(3)36(42(73)55-21-31(47)63)61-40(71)28(15-11-17-53-45(50)51)59-41(72)30(19-35(67)68)60-43(74)37(25(4)6-2)62-39(70)27(14-10-16-52-44(48)49)57-34(66)23-54-33(65)22-56-38(69)29(58-32(64)20-46)18-26-12-8-7-9-13-26/h24-30,36-37H,5-23,46H2,1-4H3,(H2,47,63)(H,54,65)(H,55,73)(H,56,69)(H,57,66)(H,58,64)(H,59,72)(H,60,74)(H,61,71)(H,62,70)(H,67,68)(H4,48,49,52)(H4,50,51,53)/t24-,25-,27-,28-,29-,30-,36-,37-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254107(CHEMBL4105659)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](C)N)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C46H83N17O12/c1-6-24(3)36(43(74)56-21-32(48)64)62-41(72)29(16-12-18-54-46(51)52)59-42(73)31(20-35(67)68)61-44(75)37(25(4)7-2)63-40(71)28(15-11-17-53-45(49)50)58-34(66)23-55-33(65)22-57-39(70)30(60-38(69)26(5)47)19-27-13-9-8-10-14-27/h24-31,36-37H,6-23,47H2,1-5H3,(H2,48,64)(H,55,65)(H,56,74)(H,57,70)(H,58,66)(H,59,73)(H,60,69)(H,61,75)(H,62,72)(H,63,71)(H,67,68)(H4,49,50,53)(H4,51,52,54)/t24-,25-,26-,28-,29-,30-,31-,36-,37-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254094(CHEMBL4076904)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C56H90N16O15/c1-5-31(3)46(54(86)63-26-41(58)74)70-51(83)36(19-13-21-61-56(59)60)67-52(84)38(25-45(78)79)68-55(87)47(32(4)6-2)71-53(85)40-20-14-22-72(40)44(77)29-62-42(75)27-64-49(81)37(24-34-17-11-8-12-18-34)66-43(76)28-65-50(82)39(30-73)69-48(80)35(57)23-33-15-9-7-10-16-33/h7,9-10,15-16,31-32,34-40,46-47,73H,5-6,8,11-14,17-30,57H2,1-4H3,(H2,58,74)(H,62,75)(H,63,86)(H,64,81)(H,65,82)(H,66,76)(H,67,84)(H,68,87)(H,69,80)(H,70,83)(H,71,85)(H,78,79)(H4,59,60,61)/t31-,32-,35+,36-,37-,38-,39-,40-,46-,47-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254093(CHEMBL4071568)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C58H97N19O15/c1-6-31(3)46(55(91)67-27-42(60)79)76-52(88)38(21-15-23-66-58(63)64)73-54(90)40(26-45(82)83)74-56(92)47(32(4)7-2)77-51(87)37(20-14-22-65-57(61)62)71-43(80)28-68-48(84)33(5)70-53(89)39(25-35-18-12-9-13-19-35)72-44(81)29-69-50(86)41(30-78)75-49(85)36(59)24-34-16-10-8-11-17-34/h8,10-11,16-17,31-33,35-41,46-47,78H,6-7,9,12-15,18-30,59H2,1-5H3,(H2,60,79)(H,67,91)(H,68,84)(H,69,86)(H,70,89)(H,71,80)(H,72,81)(H,73,90)(H,74,92)(H,75,85)(H,76,88)(H,77,87)(H,82,83)(H4,61,62,65)(H4,63,64,66)/t31-,32-,33+,36+,37-,38-,39-,40-,41-,46-,47-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254106(CHEMBL4084160)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C60H99N19O15/c1-5-33(3)48(56(92)70-29-44(62)81)77-53(89)39(21-14-24-68-60(65)66)73-54(90)41(28-47(84)85)75-57(93)49(34(4)6-2)78-52(88)38(20-13-23-67-59(63)64)72-46(83)31-69-45(82)30-71-51(87)40(27-36-18-11-8-12-19-36)74-55(91)43-22-15-25-79(43)58(94)42(32-80)76-50(86)37(61)26-35-16-9-7-10-17-35/h7,9-10,16-17,33-34,36-43,48-49,80H,5-6,8,11-15,18-32,61H2,1-4H3,(H2,62,81)(H,69,82)(H,70,92)(H,71,87)(H,72,83)(H,73,90)(H,74,91)(H,75,93)(H,76,86)(H,77,89)(H,78,88)(H,84,85)(H4,63,64,67)(H4,65,66,68)/t33-,34-,37+,38-,39-,40-,41-,42-,43+,48-,49-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254091(CHEMBL4061318)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C57H95N19O15/c1-5-31(3)46(54(90)67-26-41(59)78)75-52(88)37(20-14-22-65-57(62)63)72-53(89)39(25-45(82)83)73-55(91)47(32(4)6-2)76-51(87)36(19-13-21-64-56(60)61)70-43(80)28-66-42(79)27-68-49(85)38(24-34-17-11-8-12-18-34)71-44(81)29-69-50(86)40(30-77)74-48(84)35(58)23-33-15-9-7-10-16-33/h7,9-10,15-16,31-32,34-40,46-47,77H,5-6,8,11-14,17-30,58H2,1-4H3,(H2,59,78)(H,66,79)(H,67,90)(H,68,85)(H,69,86)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,84)(H,75,88)(H,76,87)(H,82,83)(H4,60,61,64)(H4,62,63,65)/t31-,32-,35+,36-,37-,38-,39-,40-,46-,47-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254105(CHEMBL4076901)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C57H103N23O17/c1-5-29(3)44(53(96)70-23-39(59)83)79-50(93)34(17-12-20-68-57(64)65)75-51(94)36(22-43(87)88)76-54(97)45(30(4)6-2)80-49(92)33(16-11-19-67-56(62)63)73-41(85)25-69-40(84)24-71-47(90)35(21-31-13-8-7-9-14-31)74-42(86)26-72-48(91)37(27-81)78-52(95)38(28-82)77-46(89)32(58)15-10-18-66-55(60)61/h29-38,44-45,81-82H,5-28,58H2,1-4H3,(H2,59,83)(H,69,84)(H,70,96)(H,71,90)(H,72,91)(H,73,85)(H,74,86)(H,75,94)(H,76,97)(H,77,89)(H,78,95)(H,79,93)(H,80,92)(H,87,88)(H4,60,61,66)(H4,62,63,67)(H4,64,65,68)/t29-,30-,32-,33-,34-,35-,36-,37-,38-,44-,45-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254088(CHEMBL4088351)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C60H100N20O17/c1-5-32(3)48(57(96)70-26-43(62)83)79-54(93)38(20-14-22-68-60(65)66)75-56(95)41(25-47(87)88)77-58(97)49(33(4)6-2)80-53(92)37(19-13-21-67-59(63)64)73-45(85)28-69-44(84)27-71-51(90)39(23-34-15-9-7-10-16-34)74-46(86)29-72-52(91)42(31-82)78-55(94)40(76-50(89)36(61)30-81)24-35-17-11-8-12-18-35/h8,11-12,17-18,32-34,36-42,48-49,81-82H,5-7,9-10,13-16,19-31,61H2,1-4H3,(H2,62,83)(H,69,84)(H,70,96)(H,71,90)(H,72,91)(H,73,85)(H,74,86)(H,75,95)(H,76,89)(H,77,97)(H,78,94)(H,79,93)(H,80,92)(H,87,88)(H4,63,64,67)(H4,65,66,68)/t32-,33-,36-,37-,38-,39-,40-,41-,42-,48-,49-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254087(CHEMBL4075426)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C57H95N19O15/c1-5-31(3)46(54(90)67-26-41(59)78)75-52(88)37(20-14-22-65-57(62)63)72-53(89)39(25-45(82)83)73-55(91)47(32(4)6-2)76-51(87)36(19-13-21-64-56(60)61)70-43(80)28-66-42(79)27-68-49(85)38(24-34-17-11-8-12-18-34)71-44(81)29-69-50(86)40(30-77)74-48(84)35(58)23-33-15-9-7-10-16-33/h7,9-10,15-16,31-32,34-40,46-47,77H,5-6,8,11-14,17-30,58H2,1-4H3,(H2,59,78)(H,66,79)(H,67,90)(H,68,85)(H,69,86)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,84)(H,75,88)(H,76,87)(H,82,83)(H4,60,61,64)(H4,62,63,65)/t31-,32-,35-,36-,37-,38-,39-,40-,46-,47-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254099(CHEMBL4092707)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@@H](N)CO)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C48H86N18O14/c1-5-25(3)38(45(79)58-20-33(50)68)65-43(77)30(15-11-17-56-48(53)54)63-44(78)32(19-37(72)73)64-46(80)39(26(4)6-2)66-42(76)29(14-10-16-55-47(51)52)61-35(70)22-57-34(69)21-60-41(75)31(18-27-12-8-7-9-13-27)62-36(71)23-59-40(74)28(49)24-67/h25-32,38-39,67H,5-24,49H2,1-4H3,(H2,50,68)(H,57,69)(H,58,79)(H,59,74)(H,60,75)(H,61,70)(H,62,71)(H,63,78)(H,64,80)(H,65,77)(H,66,76)(H,72,73)(H4,51,52,55)(H4,53,54,56)/t25-,26-,28-,29-,30-,31-,32-,38-,39-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254085(CHEMBL4097040)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(C)=O)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C45H80N16O12/c1-6-24(3)36(42(72)54-21-32(46)63)60-40(70)29(16-12-18-52-45(49)50)58-41(71)31(20-35(66)67)59-43(73)37(25(4)7-2)61-39(69)28(15-11-17-51-44(47)48)57-34(65)23-53-33(64)22-55-38(68)30(56-26(5)62)19-27-13-9-8-10-14-27/h24-25,27-31,36-37H,6-23H2,1-5H3,(H2,46,63)(H,53,64)(H,54,72)(H,55,68)(H,56,62)(H,57,65)(H,58,71)(H,59,73)(H,60,70)(H,61,69)(H,66,67)(H4,47,48,51)(H4,49,50,52)/t24-,25-,28-,29-,30-,31-,36-,37-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254084(CHEMBL4087769)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1CCCCC1)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C43H78N16O11/c1-5-23(3)34(40(69)53-20-30(45)60)58-38(67)28(15-11-17-51-43(48)49)56-39(68)29(19-33(63)64)57-41(70)35(24(4)6-2)59-37(66)27(14-10-16-50-42(46)47)55-32(62)22-52-31(61)21-54-36(65)26(44)18-25-12-8-7-9-13-25/h23-29,34-35H,5-22,44H2,1-4H3,(H2,45,60)(H,52,61)(H,53,69)(H,54,65)(H,55,62)(H,56,68)(H,57,70)(H,58,67)(H,59,66)(H,63,64)(H4,46,47,50)(H4,48,49,51)/t23-,24-,26-,27-,28-,29-,34-,35-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254083(CHEMBL4076102)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C46H83N17O13/c1-5-24(3)36(43(75)56-20-32(48)65)62-41(73)29(15-11-17-54-46(51)52)59-42(74)31(19-35(68)69)61-44(76)37(25(4)6-2)63-40(72)28(14-10-16-53-45(49)50)58-34(67)22-55-33(66)21-57-39(71)30(60-38(70)27(47)23-64)18-26-12-8-7-9-13-26/h24-31,36-37,64H,5-23,47H2,1-4H3,(H2,48,65)(H,55,66)(H,56,75)(H,57,71)(H,58,67)(H,59,74)(H,60,70)(H,61,76)(H,62,73)(H,63,72)(H,68,69)(H4,49,50,53)(H4,51,52,54)/t24-,25-,27-,28-,29-,30-,31-,36-,37-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254082(CHEMBL4073884)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CS)NC(C)=O)[C@@H](C)CC)C(=O)NCC(N)=O
Show InChI InChI=1S/C48H85N17O13S/c1-6-25(3)38(45(77)57-21-34(49)67)64-42(74)30(16-12-18-55-48(52)53)61-43(75)32(20-37(70)71)63-46(78)39(26(4)7-2)65-41(73)29(15-11-17-54-47(50)51)60-36(69)23-56-35(68)22-58-40(72)31(19-28-13-9-8-10-14-28)62-44(76)33(24-79)59-27(5)66/h25-26,28-33,38-39,79H,6-24H2,1-5H3,(H2,49,67)(H,56,68)(H,57,77)(H,58,72)(H,59,66)(H,60,69)(H,61,75)(H,62,76)(H,63,78)(H,64,74)(H,65,73)(H,70,71)(H4,50,51,54)(H4,52,53,55)/t25-,26-,29-,30-,31-,32-,33-,38-,39-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254096(CHEMBL4099663)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)NC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NC
Show InChI InChI=1S/C62H99N15O17/c1-9-33(3)50(59(92)64-7)74-53(86)41(22-17-23-66-62(63)65-8)70-56(89)44(28-49(83)84)72-60(93)51(34(4)10-2)75-58(91)46-26-39(80)30-76(46)48(82)29-67-52(85)35(5)68-54(87)43(25-38-20-15-12-16-21-38)71-57(90)47-27-40(81)31-77(47)61(94)45(32-78)73-55(88)42(69-36(6)79)24-37-18-13-11-14-19-37/h11,13-14,18-19,33-35,38-47,50-51,78,80-81H,9-10,12,15-17,20-32H2,1-8H3,(H,64,92)(H,67,85)(H,68,87)(H,69,79)(H,70,89)(H,71,90)(H,72,93)(H,73,88)(H,74,86)(H,75,91)(H,83,84)(H3,63,65,66)/t33-,34-,35+,39+,40-,41-,42+,43-,44-,45-,46-,47+,50-,51-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254061(CHEMBL4089530)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)NC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NC
Show InChI InChI=1S/C62H99N15O15/c1-9-35(3)50(59(90)64-7)74-53(84)41(24-17-27-66-62(63)65-8)70-56(87)44(32-49(81)82)72-60(91)51(36(4)10-2)75-58(89)46-25-18-28-76(46)48(80)33-67-52(83)37(5)68-54(85)43(31-40-22-15-12-16-23-40)71-57(88)47-26-19-29-77(47)61(92)45(34-78)73-55(86)42(69-38(6)79)30-39-20-13-11-14-21-39/h11,13-14,20-21,35-37,40-47,50-51,78H,9-10,12,15-19,22-34H2,1-8H3,(H,64,90)(H,67,83)(H,68,85)(H,69,79)(H,70,87)(H,71,88)(H,72,91)(H,73,86)(H,74,84)(H,75,89)(H,81,82)(H3,63,65,66)/t35-,36-,37+,41-,42+,43-,44-,45-,46-,47+,50-,51-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254060(CHEMBL4061379)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NC
Show InChI InChI=1S/C61H97N15O15/c1-8-34(3)49(58(89)64-7)73-52(83)40(23-16-26-65-61(62)63)69-55(86)43(31-48(80)81)71-59(90)50(35(4)9-2)74-57(88)45-24-17-27-75(45)47(79)32-66-51(82)36(5)67-53(84)42(30-39-21-14-11-15-22-39)70-56(87)46-25-18-28-76(46)60(91)44(33-77)72-54(85)41(68-37(6)78)29-38-19-12-10-13-20-38/h10,12-13,19-20,34-36,39-46,49-50,77H,8-9,11,14-18,21-33H2,1-7H3,(H,64,89)(H,66,82)(H,67,84)(H,68,78)(H,69,86)(H,70,87)(H,71,90)(H,72,85)(H,73,83)(H,74,88)(H,80,81)(H4,62,63,65)/t34-,35-,36+,40-,41+,42-,43-,44-,45-,46+,49-,50-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50254062(CHEMBL4060314)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)NC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)CNC(=O)[C@@H](CO)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CO)[C@@H](C)CC)C(=O)NC
Show InChI InChI=1S/C62H99N15O19/c1-7-33(3)50(59(94)64-5)74-53(88)39(20-15-21-66-62(63)65-6)69-56(91)42(26-49(85)86)71-60(95)51(34(4)8-2)75-58(93)45-24-37(81)28-76(45)48(84)27-67-52(87)43(30-78)72-55(90)41(23-36-18-13-10-14-19-36)70-57(92)46-25-38(82)29-77(46)61(96)44(31-79)73-54(89)40(68-47(83)32-80)22-35-16-11-9-12-17-35/h9,11-12,16-17,33-34,36-46,50-51,78-82H,7-8,10,13-15,18-32H2,1-6H3,(H,64,94)(H,67,87)(H,68,83)(H,69,91)(H,70,92)(H,71,95)(H,72,90)(H,73,89)(H,74,88)(H,75,93)(H,85,86)(H3,63,65,66)/t33-,34-,37+,38-,39-,40+,41-,42-,43+,44-,45-,46+,50-,51-/m0/s1
Affinity DataIC50: 1.00E+3nMAssay Description:Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count methodMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50112317(Atrial natriuretic peptide analogue | CHEMBL439465...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCSC)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@@H](NC(=O)[C@@H](CO)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@@H](N)CCSC
Show InChI InChI=1S/C72H110N24O19S4/c1-6-37(2)57-70(115)93-51(33-97)67(112)95-53(69(114)90-48(27-40-16-18-42(98)19-17-40)64(109)86-44(58(74)103)14-10-22-80-71(75)76)35-119-118-34-52(94-60(105)43(73)20-24-116-4)68(113)91-49(28-41-30-79-36-84-41)65(110)89-47(26-39-12-8-7-9-13-39)61(106)83-31-54(99)82-32-55(100)85-38(3)59(104)87-46(21-25-117-5)62(107)92-50(29-56(101)102)66(111)88-45(63(108)96-57)15-11-23-81-72(77)78/h7-9,12-13,16-19,30,36-38,43-53,57,97-98H,6,10-11,14-15,20-29,31-35,73H2,1-5H3,(H2,74,103)(H,79,84)(H,82,99)(H,83,106)(H,85,100)(H,86,109)(H,87,104)(H,88,111)(H,89,110)(H,90,114)(H,91,113)(H,92,107)(H,93,115)(H,94,105)(H,95,112)(H,96,108)(H,101,102)(H4,75,76,80)(H4,77,78,81)/t37-,38-,43-,44-,45+,46+,47+,48-,49-,50-,51+,52-,53+,57-/m0/s1
Affinity DataEC50:  30nMAssay Description:Production of c-GMP in CHO cells expressing natriuretic peptide receptor (NPR-A) in response to compoundMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50112316(Atrial natriuretic peptide analogue | CHEMBL384862)
Show SMILES CC[C@H](C)[C@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)CCCNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCNC(N)=N)C(N)=O)NC(=O)[C@@H](N)CCSC
Show InChI InChI=1S/C74H116N26O18S4/c1-5-39(2)58-71(118)97-53(35-101)68(115)99-55(70(117)94-50(31-41-17-19-43(102)20-18-41)65(112)90-45(59(76)106)21-27-87-74(81)82)37-122-121-36-54(98-60(107)44(75)22-28-119-3)69(116)95-51(32-42-34-83-38-88-42)66(113)93-49(30-40-12-7-6-8-13-40)61(108)84-24-11-16-56(103)89-46(14-9-25-85-72(77)78)62(109)92-48(23-29-120-4)63(110)96-52(33-57(104)105)67(114)91-47(64(111)100-58)15-10-26-86-73(79)80/h6-8,12-13,17-20,34,38-39,44-55,58,101-102H,5,9-11,14-16,21-33,35-37,75H2,1-4H3,(H2,76,106)(H,83,88)(H,84,108)(H,89,103)(H,90,112)(H,91,114)(H,92,109)(H,93,113)(H,94,117)(H,95,116)(H,96,110)(H,97,118)(H,98,107)(H,99,115)(H,100,111)(H,104,105)(H4,77,78,85)(H4,79,80,86)(H4,81,82,87)/t39-,44-,45-,46+,47-,48-,49+,50-,51-,52+,53-,54-,55-,58+/m0/s1
Affinity DataEC50:  8.30nMAssay Description:Production of c-GMP in CHO cells expressing natriuretic peptide receptor (NPR-A) in response to compoundMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50112318(Atrial natriuretic peptide analogue | CHEMBL409400)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]2CCCN2C(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@@H](NC(=O)[C@@H](CO)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@@H](N)CCSC
Show InChI InChI=1S/C78H121N27O19S4/c1-5-41(2)61-75(124)101-55(37-106)71(120)103-57(73(122)98-52(32-43-19-21-45(107)22-20-43)68(117)93-47(62(80)111)15-9-25-88-76(81)82)39-128-127-38-56(102-63(112)46(79)23-29-125-3)72(121)99-53(33-44-35-87-40-92-44)69(118)97-51(31-42-13-7-6-8-14-42)64(113)91-36-59(108)105-28-12-18-58(105)74(123)96-48(16-10-26-89-77(83)84)65(114)95-50(24-30-126-4)66(115)100-54(34-60(109)110)70(119)94-49(67(116)104-61)17-11-27-90-78(85)86/h6-8,13-14,19-22,35,40-41,46-58,61,106-107H,5,9-12,15-18,23-34,36-39,79H2,1-4H3,(H2,80,111)(H,87,92)(H,91,113)(H,93,117)(H,94,119)(H,95,114)(H,96,123)(H,97,118)(H,98,122)(H,99,121)(H,100,115)(H,101,124)(H,102,112)(H,103,120)(H,104,116)(H,109,110)(H4,81,82,88)(H4,83,84,89)(H4,85,86,90)/t41-,46-,47-,48-,49+,50+,51+,52-,53-,54-,55+,56-,57+,58+,61-/m0/s1
Affinity DataEC50:  47nMAssay Description:Production of c-GMP in CHO cells expressing natriuretic peptide receptor (NPR-A) in response to compoundMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50112319(Atrial natriuretic peptide analogue | CHEMBL412345)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@@H](NC(=O)[C@@H](CO)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@@H](N)CCSC
Show InChI InChI=1S/C76H119N27O17S4/c1-5-41(2)60-72(119)99-54(37-104)68(115)101-56(70(117)97-52(32-43-19-21-45(105)22-20-43)66(113)93-47(61(78)108)15-9-25-86-74(79)80)39-124-123-38-55(100-62(109)46(77)23-29-121-3)69(116)98-53(33-44-34-85-40-91-44)67(114)96-51(31-42-13-7-6-8-14-42)63(110)90-35-58(106)89-36-59(107)92-48(16-10-26-87-75(81)82)64(111)95-50(24-30-122-4)73(120)103-28-12-18-57(103)71(118)94-49(65(112)102-60)17-11-27-88-76(83)84/h6-8,13-14,19-22,34,40-41,46-57,60,104-105H,5,9-12,15-18,23-33,35-39,77H2,1-4H3,(H2,78,108)(H,85,91)(H,89,106)(H,90,110)(H,92,107)(H,93,113)(H,94,118)(H,95,111)(H,96,114)(H,97,117)(H,98,116)(H,99,119)(H,100,109)(H,101,115)(H,102,112)(H4,79,80,86)(H4,81,82,87)(H4,83,84,88)/t41-,46-,47-,48-,49+,50+,51+,52-,53-,54+,55-,56+,57-,60-/m0/s1
Affinity DataEC50: >1.00E+4nMAssay Description:Production of c-GMP in CHO cells expressing natriuretic peptide receptor (NPR-A) in response to compoundMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50112321(Atrial natriuretic peptide analogue | CHEMBL407206...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@@H](NC(=O)[C@@H](CO)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@@H](N)CCSC
Show InChI InChI=1S/C75H117N27O19S4/c1-5-39(2)59-72(121)99-53(35-103)69(118)101-55(71(120)96-50(29-41-17-19-43(104)20-18-41)66(115)92-45(60(77)109)14-9-23-85-73(78)79)37-125-124-36-54(100-61(110)44(76)21-26-122-3)70(119)97-51(30-42-32-84-38-90-42)67(116)95-49(28-40-12-7-6-8-13-40)62(111)89-33-56(105)88-34-57(106)91-46(15-10-24-86-74(80)81)63(112)94-48(22-27-123-4)64(113)98-52(31-58(107)108)68(117)93-47(65(114)102-59)16-11-25-87-75(82)83/h6-8,12-13,17-20,32,38-39,44-55,59,103-104H,5,9-11,14-16,21-31,33-37,76H2,1-4H3,(H2,77,109)(H,84,90)(H,88,105)(H,89,111)(H,91,106)(H,92,115)(H,93,117)(H,94,112)(H,95,116)(H,96,120)(H,97,119)(H,98,113)(H,99,121)(H,100,110)(H,101,118)(H,102,114)(H,107,108)(H4,78,79,85)(H4,80,81,86)(H4,82,83,87)/t39-,44-,45-,46-,47+,48+,49+,50-,51-,52-,53+,54-,55+,59-/m0/s1
Affinity DataEC50:  0.680nMAssay Description:Production of c-GMP in CHO cells expressing natriuretic peptide receptor (NPR-A) in response to compoundMore data for this Ligand-Target Pair
TargetAtrial natriuretic peptide receptor 1(Homo sapiens (Human))
AstraZeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50112320(Atrial natriuretic peptide analogue | CHEMBL405572...)
Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCSC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@@H](NC(=O)[C@@H](CO)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@@H](N)CCSC
Show InChI InChI=1S/C74H112N24O19S4/c1-5-39(2)59-72(117)94-52(35-99)68(113)96-54(70(115)91-49(29-41-17-19-43(100)20-18-41)65(110)87-45(60(76)105)14-9-23-82-73(77)78)37-121-120-36-53(95-61(106)44(75)21-26-118-3)69(114)92-50(30-42-32-81-38-86-42)66(111)90-48(28-40-12-7-6-8-13-40)62(107)85-33-56(101)84-34-57(102)98-25-11-16-55(98)71(116)89-47(22-27-119-4)63(108)93-51(31-58(103)104)67(112)88-46(64(109)97-59)15-10-24-83-74(79)80/h6-8,12-13,17-20,32,38-39,44-55,59,99-100H,5,9-11,14-16,21-31,33-37,75H2,1-4H3,(H2,76,105)(H,81,86)(H,84,101)(H,85,107)(H,87,110)(H,88,112)(H,89,116)(H,90,111)(H,91,115)(H,92,114)(H,93,108)(H,94,117)(H,95,106)(H,96,113)(H,97,109)(H,103,104)(H4,77,78,82)(H4,79,80,83)/t39-,44-,45-,46+,47+,48+,49-,50-,51-,52+,53-,54+,55-,59-/m0/s1
Affinity DataEC50:  4.90nMAssay Description:Production of c-GMP in CHO cells expressing natriuretic peptide receptor (NPR-A) in response to compoundMore data for this Ligand-Target Pair
Displayed 1 to 50 (of 137 total ) | Next | Last >>
Jump to: